Cited 794 times in
Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.